10 Million People Started Trading Last Year – Here’s What to Do Next

From Oxford Club | Ad

How do you make money trading?
What are the secrets pros use to beat the market day after day?
Former Chicago Board Options Exchange trader reveals all the insider tricks...

Get the Full Report Now (No Credit Card Required... Limited Time Only)

CERE Insider Trading (Cerevel Therapeutics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: N/A

Insider Buying (Last 12 Months): $5,275,357.04

Insider Selling (Last 12 Months): $0.00

Cerevel Therapeutics Insider Trading History Chart

Cerevel Therapeutics Share Price & Price History

^$25.04

▲ +0.1 (0.40%)

As of 07/29/2021 01:00 AM ET

Days: 30 | 90 | 365

Three Cryptocurrencies to Hold in 2021

From Investorplace Media | Ad

In 2021, Dogecoin went up over 12,000%. SafeMoon went up more than 20,000%...

But if you missed those gains, there is still time to get in on the digital currency boom.

Luke Lango – InvestorPlace’s resident crypto expert – just released the names of 3 tokens every investor should own in a free report.

Click here to claim your copy today.

Cerevel Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/7/2021	Perceptive Advisors Llc	Director	Buy	200,000	$25.00	$5,000,000.00
6/17/2021	Gabrielle Sulzberger	Director	Buy	21,084	$13.06	$275,357.04	35,354

Insider Buying at Cerevel Therapeutics?

Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Cerevel Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Cerevel Therapeutics (NASDAQ:CERE)

78.37% of Cerevel Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cerevel Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/18/2021	Millennium Management LLC	426,016	$5.85M	0.0%	+976.6%	0.335%
5/18/2021	Point72 Asset Management L.P.	296,700	$4.07M	0.0%	+147.3%	0.233%
5/18/2021	Verition Fund Management LLC	261,504	$3.59M	0.0%	+638.1%	0.205%
5/18/2021	Morgan Stanley	5,300	$73K	0.0%	-63.2%	0.004%
5/18/2021	Alyeska Investment Group L.P.	1,012,480	$13.90M	0.2%	-24.5%	0.796%
5/18/2021	Citadel Advisors LLC	1,226,729	$16.84M	0.0%	-11.2%	0.964%
5/18/2021	Man Group plc	13,468	$0.19M	0.0%	N/A	0.011%
5/17/2021	Schonfeld Strategic Advisors LLC	13,002	$0.18M	0.0%	N/A	0.010%
5/17/2021	Perceptive Advisors LLC	4,643,095	$63.75M	0.8%	+2.2%	3.643%
5/17/2021	Rock Springs Capital Management LP	1,005,100	$13.80M	0.3%	+0.6%	0.791%
5/17/2021	Price T Rowe Associates Inc. MD	3,399,888	$46.68M	0.0%	+0.2%	2.675%
5/17/2021	Woodline Partners LP	392,910	$5.40M	0.1%	N/A	0.309%
5/17/2021	HRT Financial LP	33,368	$0.46M	0.0%	N/A	0.026%
5/17/2021	Brookfield Asset Management Inc.	24,253	$0.33M	0.0%	-33.3%	0.019%
5/17/2021	Sphera Funds Management LTD.	912,240	$12.53M	1.0%	+12.4%	0.718%
5/17/2021	Ally Bridge Group NY LLC	1,728,590	$23.73M	4.6%	-2.2%	1.360%
5/17/2021	Goldman Sachs Group Inc.	190,266	$2.61M	0.0%	+572.1%	0.150%
5/14/2021	TD Asset Management Inc.	114,715	$1.58M	0.0%	+208.7%	0.090%
5/14/2021	Credit Suisse AG	12,947	$0.18M	0.0%	N/A	0.010%
5/13/2021	Wolverine Asset Management LLC	8,776	$0.12M	0.0%	N/A	0.007%
5/13/2021	Penserra Capital Management LLC	14,762	$0.20M	0.0%	-32.0%	0.012%
5/13/2021	Bank of New York Mellon Corp	830,788	$11.41M	0.0%	+3,739.7%	0.654%
5/13/2021	Citigroup Inc.	104,273	$1.43M	0.0%	+13.7%	0.082%
5/13/2021	Federated Hermes Inc.	1,950,000	$26.77M	0.1%	+104.9%	1.534%
5/12/2021	Northern Trust Corp	69,601	$0.96M	0.0%	+5.8%	0.055%
5/12/2021	Geode Capital Management LLC	443,791	$6.09M	0.0%	-3.3%	0.349%
5/12/2021	JPMorgan Chase & Co.	2,635	$36K	0.0%	N/A	0.002%
5/12/2021	E Fund Management Co. Ltd.	2,494	$34K	0.0%	N/A	0.002%
5/12/2021	UBS Group AG	8,403	$0.12M	0.0%	-37.2%	0.007%
5/10/2021	HighTower Advisors LLC	66,544	$0.91M	0.0%	+46.8%	0.052%
5/10/2021	Rafferty Asset Management LLC	61,585	$0.85M	0.0%	N/A	0.048%
5/7/2021	BlackRock Inc.	1,097,571	$15.07M	0.0%	+0.2%	0.863%
3/26/2021	Susquehanna International Group LLP	22,500	$0.37M	0.0%	N/A	0.018%
2/25/2021	Hsbc Holdings PLC	21,003	$0.36M	0.0%	N/A	0.017%
2/24/2021	Virtu Financial LLC	15,478	$0.26M	0.0%	N/A	0.012%
2/24/2021	Alyeska Investment Group L.P.	1,341,485	$22.24M	0.3%	N/A	1.055%
2/18/2021	Verition Fund Management LLC	35,430	$0.59M	0.0%	N/A	0.028%
2/16/2021	Alyeska Investment Group L.P.	1,341,485	$22.24M	0.3%	N/A	1.055%
2/16/2021	Brookfield Asset Management Inc.	36,355	$0.60M	0.0%	N/A	0.029%
2/16/2021	Price T Rowe Associates Inc. MD	3,392,133	$54M	0.0%	N/A	2.668%
2/16/2021	ExodusPoint Capital Management LP	49,992	$0.83M	0.0%	N/A	0.039%
2/16/2021	Charles Schwab Investment Management Inc.	166,710	$2.77M	0.0%	N/A	0.131%
2/12/2021	Penserra Capital Management LLC	21,701	$0.36M	0.0%	N/A	0.017%
2/12/2021	Federated Hermes Inc.	951,700	$15.78M	0.0%	N/A	0.749%
2/11/2021	Northern Trust Corp	65,805	$1.09M	0.0%	N/A	0.052%
2/11/2021	Citigroup Inc.	91,743	$1.52M	0.0%	N/A	0.072%
2/11/2021	Artal Group S.A.	2,282,100	$37.84M	0.8%	N/A	1.795%
2/11/2021	Monashee Investment Management LLC	200,000	$3.32M	0.4%	N/A	0.157%
2/10/2021	HighTower Advisors LLC	45,325	$0.75M	0.0%	N/A	0.036%
2/9/2021	Bank of New York Mellon Corp	21,637	$0.36M	0.0%	N/A	0.017%
2/5/2021	BlackRock Inc.	1,095,391	$18.16M	0.0%	N/A	0.862%
1/29/2021	Creative Planning	13,401	$0.22M	0.0%	N/A	0.011%
1/19/2021	LGT Capital Partners LTD.	144,254	$2.39M	0.1%	N/A	0.113%
5/13/2016	Sabby Management LLC	720,378	$0.16M	0.0%	+26.2%	4.906%
2/16/2016	Frigate Ventures LP	4,728,318	$1.54M	0.5%	N/A	32.198%

Data available starting January 2016

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $25.04

$24.55

$25.23

50 Day Range

MA: $18.28

$12.56

$29.69

52 Week Range

Now: $25.04

$9.00

$31.09

Volume

376,543 shs

Average Volume

1,110,694 shs

Market Capitalization

$3.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Cerevel Therapeutics?

Cerevel Therapeutics' top insider investors include:

Gabrielle Sulzberger (Director)
Perceptive Advisors Llc (Director)

10 Million People Started Trading Last Year – Here’s What to Do Next

From Oxford Club | Ad

How do you make money trading?
What are the secrets pros use to beat the market day after day?
Former Chicago Board Options Exchange trader reveals all the insider tricks...

Get the Full Report Now (No Credit Card Required... Limited Time Only)